At a prespecified analysis of the CARTITUDE-1 trial with a median follow-up of approximately 28 months, treatment with cilta-cel continued to elicit positive responses and maintained a favorable risk/benefit profile for patients with multiple myeloma.
Expert Marks Anti-VISTA/Anti-PD-1 Therapies as a Potential New Strategy for Advanced Solid TumorsMarch 20th 2023
Anti-VISTA therapy may be the therapy type to be used with PD-1/PD-L1 inhibitors to treat patients with advanced solid tumors, expert say. One agent, KVA12123, has just entered phase 1 clinical research.
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast CancerMarch 20th 2023
Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Leveraging ctDNA to Predict Response in Patients With Myeloma Receiving CAR T CellsMarch 20th 2023
In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.
Coformulation of Pembrolizumab/Vibostolimab Fails to Show PFS Benefit in NSCLCMarch 20th 2023
The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer
Trial to Assess PRT2527 Plus Zanubrutinib for Hematologic MalignanciesMarch 18th 2023
The combination of CDK9 plus BTK inhibition has already demonstrated synergistic clinical efficacy vs BTK inhibition alone. Now, a clinical trial collaboration will evaluate PRT2527 and zanubrutinib for patients with hematologic malignancies.
Clinicians Must Address Unusual AEs of BRAF/MEK Inhibition for BRAF-Mutated NSCLCMarch 17th 2023
A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.
Enzalutamide/Leuprolide Extends MFS in nmHSPC With High-Risk Bochemical RecurrenceMarch 17th 2023
The phase 3 EMBARK trial of enzalutamide plus leuprolide is the first to elicit a statistically significant improvement in metastasis-free survival in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade GliomaMarch 16th 2023
Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.
Molecular Targets Making Headway in Pediatric Thyroid Cancer ResearchMarch 16th 2023
In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.
Enzalutamide Plus ADT Improves Time to PSA Progression in mHSPCMarch 15th 2023
Investigators from the China ARCHES trial of enzalutamide plus androgen deprivation therapy announced that it had met its primary end point in Chinese patients with metastatic hormone-sensitive prostate cancer.
FDA Awards Orphan Drug Designation to EP0042 for AML TreatmentMarch 15th 2023
Preclinical and phase 1/2a data evaluating the safety and tolerability of EP0042 in patients with relapsed or refractory acute myeloid leukemia has led the FDA to grant an orphan drug designation to the agent.
ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+/HER2- Breast CancerMarch 15th 2023
Promising findings from the phase 2 ELAINE-1 and ELAINE-2 trials have led to the start of a phase 3 study where investigators will evaluate lasofoxifene and abemaciclib as a treatment for patients with ER-positive/HER2-negative breast cancer and an ESR1 mutation.
Phase 1b/2a Trial of Bemcentinib and SOC Doses First Patient With STK11m NSCLCMarch 11th 2023
A phase 1b/2a trial is investigating the combination of bemcentinib with pembrolizumab and doublet chemotherapy in patients with first-line non–small cell lung cancer that harbors STK11 mutations.
FDA OKs Pegfilgrastim Biosimilar to Decrease Chemo-Associated Febrile NeutropeniaMarch 10th 2023
A comprehensive analytical data package and pharmacokinetic, pharmacodynamic, and immunogenicity study has led the FDA to approve the pegfilgrastim biosimilar pegfilgrastim-cbqv for patients with cancer.